1. Azizi M, Rossignol P, et al. Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension. 2019;74:1075-1083. DOI: 10.1161 /HYPERTENSIONAHA.119.12676
2. Upadhya B, Kozak PM, et al. Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Curr Hypertens Rep. 2022 Jan;24(1):1-20. doi: 10.1007/s11906-022-01166-9. Epub 2022 Feb 14. PMID: 35165832.
3. Bozkurt B, Nair AP, et al. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions. JACC Basic Transl Sci. 2022 Sep 7;8(1):88-105. doi: 10.1016/j.jacbts.2022.05.010. PMID: 36777165; PMCID: PMC9911324.
4. Kario K. The sacubitril/valsartan, a first-in-class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): potential uses in hypertension, heart failure, and beyond. Curr Cardiol Rep.2018;20:5.doi: 10.1007/s11886-018-0944-4
5. Zhao Y, Yu H, et al. The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2017;22:447–457. doi: 10.1177/1074248417693379
6. Sandner P. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. Biol Chem. 2018;399:679–690.doi: 10.1515/hsz-2018-0155.
7. Abuelazm MT, Attia A, et al. Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction. Egypt Heart J. 2024 Jan 24;76(1):6. doi: 10.1186/s43044-024-00437-x. PMID: 38265696; PMCID: PMC10808080.
8. Pérez-Gordillo FL, Serrano-Morillas N, et al. Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists. Int J Mol Sci. 2023 Jan 26;24(3):2439. doi: 10.3390/ijms24032439. PMID: 36768761; PMCID: PMC9917360.
9. Llorens-Cortes C, Touyz RM. Evolution of a New Class of Antihypertensive Drugs: Targeting the Brain Renin-Angiotensin System. Hypertension. 2020 Jan;75(1):6-15. doi: 10.1161/HYPERTENSIONAHA.119.12675. Epub 2019 Dec 2. PMID: 31786978.
10. Marc Y, et al. Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Hypertension. 2012;60:411–418. doi: 10.1161/HYPERTENSIONAHA.112.190942
11. Ferdinand KC, Balavoine F, et al. Efficacy and safety of firibastat, a first-inclass brain aminopeptidase a inhibitor, in hypertensive overweight patients of multiple ethnic origins. A phase 2, open-label, multicenter, dose-titrating study. 040070 Circulation. 2019;140:138–146. doi: 10.1161/CIRCULATIONAHA.119.
12. Urmila A, Rashmi P, et al. Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It. J Renin Angiotensin Aldosterone Syst. 2021 Nov 30;2021:9293553. doi: 10.1155/2021/9293553. PMID: 34925551; PMCID: PMC8651430.
13. Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16:491–502. doi: 10.1038/s41569-019-0176-3
14. Liu C, Chen J, et al. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD004434. doi: 10.1002/14651858.CD004434.pub6. PMID: 33765691; PMCID: PMC8094512.
15. Martínez-Díaz I, Martos N, et al. Endothelin Receptor Antagonists in Kidney Disease. Int J Mol Sci. 2023 Feb 8;24(4):3427. doi: 10.3390/ijms24043427. PMID: 36834836; PMCID: PMC9965540.
16. Gupta R, Maitz T, et al. SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure. Trends Cardiovasc Med. 2023 Nov;33(8):479-486. doi: 10.1016/j.tcm.2022.05.005. Epub 2022 May 18. PMID: 35597430.
17. Zhang Q, Zhou S, et al. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023 Jun 7;15(1):118. doi: 10.1186/s13098-023-01092-z. PMID: 37280615; PMCID: PMC10246111.